anti-CXCR2 nanobody (Ablynx/Novartis)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-CXCR2 nanobody (Ablynx/Novartis)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment
Mechanisms of ActionC-X-C motif chemokine receptor 2 antagonists
TargetsC-X-C motif chemokine receptor 2
Therapy Area/IndicationsInflammation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumSwitzerland
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAblynx Nv
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis AgAblynx Nv
Active IndicationsN/A
Inactive IndicationsInflammation

Other Information

ATC CodeN/A
Related LinksN/A